AYTU BIOPHARMA, INC Business Combination, Acquisition Related Costs
AYTU BIOPHARMA, INC (AYTU) reported Business Combination, Acquisition Related Costs of $0 for the 12-month period ending 2022-06-30, per its 10-K filed 2022-09-27.
Discontinued › Expense Statement › Operating Expenses
us-gaap:BusinessCombinationAcquisitionRelatedCosts · last filed 2022-09-27
- AYTU BIOPHARMA, INC business combination, acquisition related costs for the quarter ending 2021-06-30 was $70.00K, a 91.40% decline year-over-year.
- AYTU BIOPHARMA, INC business combination, acquisition related costs for the quarter ending 2021-03-31 was $1.54M, a 394.08% increase year-over-year.
- AYTU BIOPHARMA, INC business combination, acquisition related costs for the quarter ending 2020-12-31 was $1.31M.
- AYTU BIOPHARMA, INC business combination, acquisition related costs for the quarter ending 2020-06-30 was $814.28K.
- AYTU BIOPHARMA, INC business combination, acquisition related costs for fiscal 2022 was $0.00, a 100.00% decline from fiscal 2021.
- AYTU BIOPHARMA, INC business combination, acquisition related costs for fiscal 2021 was $2.92M, a 24.32% increase from fiscal 2020.
- AYTU BIOPHARMA, INC business combination, acquisition related costs for fiscal 2020 was $2.35M.
| Period end | Business Combination, Acquisition Related Costs 3 month | Business Combination, Acquisition Related Costs 3 month as first filed | Business Combination, Acquisition Related Costs 6 month | Business Combination, Acquisition Related Costs 9 month | Business Combination, Acquisition Related Costs 9 month as first filed | Business Combination, Acquisition Related Costs 12 month |
|---|---|---|---|---|---|---|
| 2022-06-30 | $0.00 10-K · filed 2022-09-27 | |||||
| 2021-06-30 | $70.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-09-27 | $1.61M derived: sum of 2 quarters · filed 2022-09-27 | $2.92M derived: sum of 3 quarters · filed 2022-09-27 | $2.92M 10-K · filed 2022-09-27 | ||
| 2021-03-31 | $1.54M 10-Q · filed 2022-05-16 | $1.54M 10-Q · filed 2021-05-17 | $2.85M derived: sum of 2 quarters · filed 2022-05-16 | $2.85M 10-Q · filed 2022-05-16 | $2.85M 10-Q · filed 2021-05-17 | |
| 2020-12-31 | $1.31M 10-Q · filed 2022-02-14 | $1.31M 10-Q · filed 2022-02-14 | ||||
| 2020-06-30 | $814.28K derived: 10-K 12 month − 10-Q 9 month · filed 2021-09-28 | $1.13M derived: sum of 2 quarters · filed 2021-09-28 | $2.35M 10-K · filed 2021-09-28 | |||
| 2020-03-31 | $311.08K 10-Q · filed 2021-05-17 | $1.53M 10-Q · filed 2021-05-17 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NextCure, Inc. (NXTC) | United States | $0.024B | -0.15 |
| TherapeuticsMD, Inc. (TXMD) | United States | $0.024B | -117.87 |
| ARTELO BIOSCIENCES, INC. (ARTL) | United States | $0.023B | |
| KYNTRA BIO, INC. (KYNB) | United States | $0.028B | 0.17 |
| Transcode Therapeutics, Inc. (RNAZ) | United States | $0.029B | -0.12 |
| Cocrystal Pharma, Inc. (COCP) | United States | $0.022B | |
| Hepion Pharmaceuticals, Inc. (HEPA) | United States | $0.029B | -0.62 |
| ATOSSA THERAPEUTICS, INC. (ATOS) | United States | $0.021B | -0.52 |
| IGC Pharma, Inc. (IGC) | United States | $0.029B | -5.98 |
| Neuphoria Therapeutics Inc. (NEUP) | United States | $0.020B | -1.77 |